Full Press Release Details
Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA nephropathy.
ZLAB
Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA nephropathy
Key Takeaway: Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA nephropathy
Price reaction · baseline $17.69 (2026-05-29 close) · 1 other ZLAB headline(s) in the window, move may be shared
day 0 close · peak
-3.4%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+48%
120-day peak, hindsight
Typical move
2.3%
average across 15 past catalysts
Cash runway
~27 mo
Low dilution risk
Lead asset
ZL-1310
Phase 3 · Extensive-Stage Small Cell Lung Cancer